SIGY Stock Overview
A development-stage company, provides therapeutic solutions to treat cancer and infectious disease disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sigyn Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.53 |
| 52 Week High | US$5.75 |
| 52 Week Low | US$3.15 |
| Beta | -0.82 |
| 1 Month Change | -14.94% |
| 3 Month Change | -14.32% |
| 1 Year Change | -32.76% |
| 3 Year Change | -64.70% |
| 5 Year Change | n/a |
| Change since IPO | -95.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| SIGY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 5.3% |
| 1Y | -32.8% | 9.5% | 11.9% |
Return vs Industry: SIGY underperformed the US Medical Equipment industry which returned 9.5% over the past year.
Return vs Market: SIGY underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| SIGY volatility | |
|---|---|
| SIGY Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SIGY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SIGY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 4 | Jim Joyce | www.sigyntherapeutics.com |
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.
Sigyn Therapeutics, Inc. Fundamentals Summary
| SIGY fundamental statistics | |
|---|---|
| Market cap | US$5.67m |
| Earnings (TTM) | -US$3.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs SIGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIGY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.34m |
| Earnings | -US$3.34m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -46.3% |
How did SIGY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 22:42 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sigyn Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Siddharth Rajeev | Fundamental Research Corp. |